In line with these data, the results of our study in mCRC patients undergone TSPP vaccination suggested that the number of previous treatments, age, gender, treatment arm (A, B or C), HLA-A(*)02.01 haplotype, TS levels and TIL immune-phenotype in the tumor, at baseline, were not able to influence the outcome of these patients. This evidence concerns the gene TYMS and neoplasm.